The development of antibody-based strategies for the treatment of multiple myeloma (MM) has been hampered so far by the fact that suitable plasma cell-specific surface antigens have been missing. However, recently a novel monoclonal antibody, designated Wue-1, has been generated that specifically recognizes normal and malignant human plasma cells. Therefore, Wue-1 is an interesting and promising candidate to develop novel immunotherapeutic strategies for the treatment of MM. One variant for an antibody-based strategy is the bispecific antibody approach. Recombinant bispecific single-chain (bsc) antibodies are especially interesting candidates because they show exceptional biological properties. We have generated a novel MM-directed recombinant bsc antibody, bscWue-1 Â CD3, and analyzed the biological properties of this antibody using the MM cell line NCI-H929 and primary cells from the bone marrow of patients with MM. We were able to show that bscWue-1 Â CD3 induces efficient and selective T-cell-mediated cell death of NCI-H929 cells and primary myeloma cells in nine out of 11 cases. The bscWue-1 Â CD3 Ab is efficacious even at low E:T ratios, and with or without additional T-cell pre-or costimulation. Target cell lyses were specific for Wue-1 antigen-positive cells and could be blocked by the Wue-1 monoclonal antibody.
Introduction
Multiple myeloma (MM) is a malignant disorder of the terminally differentiated B cell (for instance, plasma cell) mainly localized in the bone marrow. The disorder is frequently accompanied by monoclonal (M) protein production and either diffuse osteoporosis or lytic bone lesions. Common complications of overt MM include recurrent bacterial infections, anemia, bone destruction, hypercalcemia, and renal failure. 1 Despite some progress with high-dose chemotherapy and autologous stem cell/bone marrow transplantation, MM is still an incurable disease with a median survival rate of about 3-5 years. [1] [2] [3] [4] This bleak situation has stimulated the search for alternative therapeutic strategies among which immunotherapeutic strategies play an increasing role. Tumor vaccination strategies have been developed and shown to activate idiotypespecific T-cell clones in MM patients in different settings. The therapeutic significance of this observation is currently being investigated in clinical trials, particularly as an option for the treatment of minimal residual disease after high-dose chemotherapy. 5, 6 Another immunotherapeutic strategy is the application of monoclonal antibodies that have been shown to be efficacious in various malignancies including malignant lymphomas. [7] [8] [9] However, in contrast to other B-cell nonHodgkin lymphomas, antibody-based therapies in MM are not established. One main reason for this is the fact that, so far, suitable plasma cell-specific surface antigens have been missing. 1, [10] [11] [12] Although normal and malignant plasma cells express a number of well characterized surface markers, none have turned out to be plasma cell specific: for example, CD38 is an activation rather than a differentiation-associated antigen lacking lineage restriction; 13 CD56 is an N-CAM splice variant also expressed on NK-cells;
14 CD138 (syndecan-1) is also expressed on epithelia, 15 and a recently described plasma cellassociated antigen HM1.24 has turned out to be also expressed by other cell types such as bone marrow stromal cells. 16 The expression of Muc-1 core protein was reported to be expressed only on subsets of MM cells. 11 Moreover, typical B-cell lineage markers such as CD19 or CD20 are not, or only poorly, expressed by MM cells. 1, 4 Recently, a novel monoclonal antibody, designated Wue-1, was generated that specifically binds to normal and malignant human plasma cells. When analyzing various tissues by immunohistochemistry, Wue-1 mAb was not reactive with all normal tissues tested. Strong staining could be detected exclusively in normal plasma cells and in all cases of MM analyzed. 12 Expression profile and biochemical characteristics discriminate the Wue-1 antigen from other plasma cellassociated antigens described so far, 12 although the molecular identity is still unclear and therefore under current investigation. As of the highly selective expression pattern, Wue-1 could be a promising candidate to develop novel immunotherapeutic strategies for the treatment of MM.
An interesting variant of an antibody-based strategy are bispecific antibodies. By joining two different antigen-binding sites in one antibody molecule, redirection of effector cells to a predefined tumor target can be achieved. Although bispecific antibodies are efficient in recruiting cytotoxic effector cells against tumor cells in vitro and in vivo, [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] large randomized clinical trials as a final test of therapeutic efficacy are still lacking. The main reason for this are difficulties in producing sufficient amounts of clinical grade material. The production and purification processes are inefficient, with low yields regardless of whether a hybrid-hybridoma approach, chemical linkage, or renaturation from bacterial inclusion bodies of recombinant Fab or Fv fragments was followed. In addition, nearly all of these products are plagued by contamination with ill-defined by-products. 26, 27, [30] [31] [32] [33] As we have previously shown with two different bispecific single-chain (bsc) antibodies (EpCAM Â CD3 and CD19 Â CD3), these handicaps can be overcome with a molecular format linking the variable regions of two antibodies in the configuration V light-chain (V L )1-V heavy-chain (V H )1-V H 2-V L 2 on one peptide chain. [34] [35] [36] The resulting recombinant molecule produced by mammalian cells is secreted at high yields in a fully active form that requires no further renaturation. Another advantage of these recombinant bsc antibodies compared to other antibody formats is their exceptionally strong biological activity. 37, 38 Moreover, the small size is expected to improve the penetration into malignant tissues, thus further increasing the potential therapeutic efficacy. 39 Owing to the promising biological properties of bsc antibodies, the very same molecular format was chosen to produce a recombinant antibody construct directed against the Wue-1 and the CD3 antigen (bscWue-1 Â CD3) in pursuit of a future therapeutic trial in patients with MM. To our knowledge, the bscWue-1 Â CD3 molecule presented here is the first MM cell-directed bispecific antibody described so far.
Materials and methods

Cell lines and chemicals
NCI-H929 and NALM-6 cells were obtained from the 'Deutsche Sammlung von Mikroorganismen und Zellkulturen' (DSMZ, Braunschweig, Germany). Cell lines were cultured in complete RPMI 1640 (Biochrom, Berlin, Germany) with 10% fetal calf serum (FCS) (GIBCO, Karlsruhe, Germany). All chemicals were of research grade and obtained from Sigma, Deisenhofen, Germany or Merck, Darmstadt, Germany.
Cloning of variable immunoglobulin domains
The V L and V H domains from the Wue-1 hybridoma 12 were cloned according to standard PCR methods as described before. 40 cDNA synthesis was carried out with oligo-dT primers and reverse transcriptase. For the amplification of the V domains by PCR, we used degenerate primers based on the description of Dü bel et al. 41 The resulting fragments were cloned into the pGEM-T plasmid (Promega, Mannheim, Germany) and sequenced. The DNA of the anti-CD3 scFv fragment was provided by Traunecker. 42 
Construction of bsc fragments
To obtain the anti-Wue-1 scFv fragment, the corresponding V L and V H regions were cloned into separate plasmid vectors as templates for a V L -and V H -specific PCR using the oligonucleotide primer pairs 5 0 V L B5RRV/3 0 V L GS15 and 5 0 V H GS15/ 3 0 V H BspEI, respectively. Overlapping complementary sequences were introduced into the PCR products that combined to the coding sequence of a 15-amino-acid glycine-serine (G 4 S 1 ) 3 linker during the subsequent fusion PCR. This amplification step was performed with the primer pair 5 0 V L B5RRV/ 3 0 V H BspEI, and the resulting product (encoding the anti-Wue-1 scFv fragment) was directly cloned into the TA-cloning vector pGEM-T (Promega, Mannheim, Germany). The anti-Wue-1 fragment was excised from the pGEM-T vector by partial digestion with EcoRV and complete digestion with BspEI and cloned EcoRV/BspEI into the bluescript KS vector (Stratagene, La Jolla, USA) containing the (EcoRI/SalI-cloned) coding sequence of the bsc antibody EpCAM Â CD3. 34 Thereby, the anti-EpCAM specificity was replaced by the anti-Wue-1 fragment, preserving the 5-amino-acid (G 4 S 1 ) linker that connects to the C-terminal anti-CD3 scFv fragment. Subsequently, the DNA fragment encoding the bsc antibody Wue-1 Â CD3 with the domain arrangement V L Wue-1-V H Wue-1-V H CD3-V L CD3 was subcloned into the EcoRI/SalI sites of the expression vector pEF-DHFR. 34 The resulting plasmid DNA was transfected into DHFR-deficient Chinese hamster ovary cells by electroporation. Selection and gene amplification were performed as described previously. 34 List of primers (5 0 -3 0 , IUPAC code) 
Protein purification
The bsc antibody was purified from the cell-culture supernatant in a three-step process including ion exchange chromatography, immobilized metal affinity chromatography via a C-terminal 6 Â Histidin-Tag and gel filtration.
Protein concentrations were determined using the Bio-Rad protein assay with IgG (Bio-Rad, Mü nchen, Germany) as standard protein.
The Aekta FPLC System (Pharmacia, Stockholm, Sweden) and Unicorn Software were used for chromatography. All chemicals were of research grade and purchased from Sigma (Deisenhofen, Germany) or Merck (Darmstadt, Germany).
SDS-PAGE analysis
SDS-PAGE under reducing conditions was performed with precast 4-12% Bis/Tris gels (NOVEX). The preparation and application of samples was according to the manufacturer's protocol. The gel was stained with colloidal Coomassie. The molecular weight was determined with MultiMark protein standard (NOVEX/Invitrogen, Karlsruhe, Germany).
Immunocytochemistry
(1) Patients and specimen: Normal and tumor biopsy tissues were kept at À701C as snap-frozen blocks until sections were prepared at the time of the experiments. Tumor samples were selected from the German lymph node registry of the Institute of Pathology in Wü rzburg, and classified according to WHO classification. 43 For diagnostic purposes, the morphological and immunophenotypical analyses of paraffin-embedded and fresh-frozen sections were performed by standard methods. 12 (2) Immunostaining: Immunostaining was performed on 4-mm sections or on cytospins. The immunoperoxidase method was applied by a three-step incubation procedure with diluted affinity-purified anti-mouse antibodies (Dako, Hamburg, Germany) as described in detail elsewhere.
12,44
BscWue-1 Â CD3 Ab was detected by an anti-His-Tag antibody (Dianova, Hamburg, Germany).
FACS analysis of Wue-1 and CD19 expression
A total of 5 Â 10 5 cells were washed with phosphate-bufferedsaline (PBS) and resuspended in 100 ml PBS with 10% Venimmun (Aventis Behring, Mü nchen, Germany) and 0.1% NaN 3 . For the analysis of Wue-1 antigen, cells were incubated with Wue-1-mouse ascites for 30 min. Mouse IgG1 was used as isotype control. After washing, cells were incubated with a phycoerythrin (PE)-labeled goat-anti-mouse F(ab 2 ) fragment (Dianova, Hamburg, Germany) for 30 min. For the analysis of CD19 surface expression, cells were incubated with a PElabeled anti-CD19 mAb (Biosource, Solingen, Germany) for 30 min. Mouse IgG1-PE was used as isotype control. Flow cytometry analysis was performed in a 'FACScalibur' flow cytometer, using 'Cell-Quest' software (Becton Dickinson, Heidelberg, Germany).
Enrichment of myeloma cells from bone marrow aspirates of MM patients
Mononuclear cells from bone marrow aspirates of MM patients were separated by Ficoll density-gradient centrifugation, incubated for 15 min with anti-CD138-coated paramagnetic beads at 41C, and separated in a magnet (Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturer's protocol. To estimate the efficiency and specificity of the isolation procedure, cytospins of the enriched cells were analyzed by morphology after Pappenheim staining. The purity of the myeloma cell preparations was 490% in all experiments. Patient cells were taken from routine diagnostic specimens after informed consent of the patients and approval by the local ethics committee.
Enrichment of primary CLL cells from the peripheral blood of CLL patients
Primary CLL cells were enriched by Ficoll density-gradient centrifugation of peripheral blood from two different CLL patients with leukocyte counts 4150 000/ml containing over 95% CD19 þ lymphocytes. No further processing was performed.
Enrichment of PBMC and T cells from buffy coats
Human PBMC were isolated from fresh buffy coats of random donors by density-gradient centrifugation. Monocytes and macrophages were depleted by adhesion to cell-culture flasks for 2 h. CD19 þ B cells were depleted from the remaining cell suspension using anti-CD19-coated paramagnetic beads (Dynal, Hamburg, Germany), according to the manufacturer's protocol. This procedure resulted in a T-cell population of 490% purity, as determined by flow-cytometry after staining CD3 (data not shown). In the experiments with primary myeloma cells, the depletion of CD19 þ cells was omitted.
Cytotoxicity assays
Cytotoxicity assays using myeloma cell lines, enriched primary myeloma cells from bone marrow aspirates and CLL cells from the peripheral blood as target cells (PKH assay): Cytotoxicity assays were performed as described elsewhere. 36 Briefly, target cells were labeled with the cell-membrane-dye PKH-26 (Sigma, Deisenhofen, Germany), according to the manufacturer's protocol. Cells were incubated in 96-or 24-well flat-bottom culture plates (Nunc, Wiesbaden, Germany) in RPMI/10% FCS at indicated effector:target ratios. The experiments with enriched primary myeloma and primary CLL cells were performed in the presence of PHA (10 ng/ml) and IL-2 (60 U/ml). No additional stimulation of T cells with PHA or IL-2 was performed in the experiments with cell lines. After 48 h (cell lines) or 4-6 days (primary MM and CLL samples), cells were washed twice with PBS and stained with propidium iodide (PI) (2.5 mg/ml). Analysis was performed on a 'FACScalibur' flow cytometer using 'Cell-Quest' software (Becton Dickinson, Heidelberg, Germany) by counting 5-10 Â 10 4 cells. Specific cytotoxicity was calculated by comparing the relative number of PI-negative/PKH-positive cells (viable target cell fraction) in the bscWue-1 Â CD3 samples with the viable target cell fraction in the bscEpCAM Â CD3 Ab control samples using the following formula: 100 Â (1À(number of viable target cell fraction in the bscWue-1 Â CD3 sample)/(number of viable target fraction in the bscEpCAM Â CD3 control)). The same formula was used to calculate specific cytotoxicity against the CLL cells induced by the bscCD19 Â CD3 antibody. To rule out that the decrease of the fraction of target cells was due to the proliferation of T cells during the assay time, a correlation to absolute cell counts was carried out by two methods: counting viable cells in the Neubauer chamber under the microscope at the beginning and at the end of the incubation period or by FACS analysis using CaliBRITE beads (Becton Dickinson, San Jose, USA). With both methods no increase in absolute cell number could be detected, indicating that T-cell proliferation is not responsible for the decrease of the fraction of target cells (error o715%). Since no cell aggregates could be detected morphologically or in the FACS analysis, it is unlikely that the bscWue-1 Â CD3 interferes with the ability to count single cells.
Cytotoxicity assays with the mononuclear cell fraction from bone marrow aspirates of MM patients: Mononuclear cells from bone marrow aspirates of MM patients (including T cells and MM cells from the same patient) were separated by Ficoll density-gradient centrifugation. The T-cell to myeloma cell ratio was determined by flow cytometry using CD3 as the T-cell marker and CD138 as the myeloma cell marker. Cells were incubated in 24-well flat-bottom culture plates (Nunc, Wiesbaden, Germany) in RPMI/10% FCS. No additional stimulation of T cells with PHA or IL-2 was performed. After 4 to 6 days, cells were washed twice with PBS and stained with PI (2.5 mg/ml) and FITC-labeled anti-CD138-mAb (Biosource, Solingen, Germany). FACS analysis was performed as described above. Specific cytotoxicity was calculated by comparing the number of viable target cells in the respective samples with the bscEpCAM Â CD3 Ab control sample using the same formula as described above.
Results
bscWue-1 Â CD3 Ab binds to Wue-1 antigen-positive myeloma cells
The specific expression of the Wue-1 antigen on normal and malignant plasma cells has been demonstrated in a previous study. 12 Within malignant disorders of the lymphohematopoietic system, the Wue-1 antigen is exclusively expressed by MM and immunocytoma cells, reflecting its association with terminal B-cell differentiation. 12 Here, the expression of the Wue-1 This selective expression pattern prompted us to develop a new bsc antibody directed against the Wue-1 antigen.
The bscWue-1 Â CD3 Ab was cloned, expressed, and purified as described before for similar constructs.
34,37 SDS-PAGE analysis revealed a purity of 495% and an apparent molecular weight of approximately 54 kDa for monomeric bscWue-1 Â CD3 (Figure 1c) . By immunocytochemistry, we could demonstrate the binding of the bscWue-1 Â CD3 Ab to Wue-1-positive NCI-H929 MM cells (Figure 1a) , whereas the bscCD19 Â CD3 antibody showed no binding to NCI-H929 cells (Figure 1b) .
bscWue-1 Â CD3 Ab induces specific lysis of the Wue-1 antigen-positive myeloma cell line NCI-H929 but not of Wue-1-negative NALM-6 lymphoma cells
After we showed that the bscWue-1 Â CD3 Ab binds to MM cells, we next tested whether this novel recombinant antibody was able to specifically induce T-cell-mediated lysis of MM cells.
The MM cell line NCI-H929 expresses the Wue-1 antigen but lacks the expression of CD19. On the other hand, the Blymphoma cell line NALM-6 is negative for the Wue-1 antigen but positive for CD19 (Figure 2) . Therefore, we used these two cell lines to analyze target cell and antigen specificity of the bscWue-1 Â CD3 Ab, and performed an experiment with enriched effector T cells of healthy human donors and a mixed target cell population consisting of NCI-H929 and NALM-6 cells. This mixed target cell population was used in order to rule out any 'bystander' cytotoxicity induced by the bscWue-1 Â CD3 Ab by demonstrating that even in the presence of activated T cells cytotoxicity is strictly dependent on antibodymediated interaction of effector and target cells. Therefore, we labeled either NCI-H929 or NALM-6 cells with the membranedye PKH-26. The 1:1 mixture of labeled and unlabeled target cells was incubated with unlabeled effector T cells (E:T ratio 10:1) and with the bscWue-1 Â CD3 Ab, bscEpCAM Â CD3 Ab or bscCD19 Â CD3 Ab. All three antibodies share the same molecular format but recognize the EpCAM antigen (mainly found on epithelial tissues) 34 , the CD19 antigen (specifically expressed on normal B cells and B-lymphoma cells 37 ), or the Wue-1 antigen (specifically expressed on plasma and MM cells), while sharing an identical anti-CD3-binding site. Upon incubation with the bscWue-1 Â CD3 Ab, we observed specific lysis of NCI-H929 cells only, whereas no lysis of Wue-1-negative NALM-6 cells was seen. On the other hand, the bscCD19 Â CD3 Ab induced lysis of NALM-6 cells, but had no cytotoxic effect towards NCI-H929 cells. Incubation with the bscEpCAM Â CD3 mAb did not induce lysis of NCI-H929 or NALM-6 cells ( Figure 3 ). Neither cell line expressed the EpCAM antigen (data not shown). In the absence of effector T cells, no cytotoxic effects of bscWue-1 Â CD3 could be observed since cytotoxicity was reduced by 87% after the removal of T cells.
To further characterize the cytotoxic effect of bscWue-1 Â CD3 Ab, NCI-H929 cells were incubated with effector T cells derived from random healthy donors, and increasing amounts of bscWue-1 Â CD3 Ab. Here, we could demonstrate dose-dependent lysis of NCI-H929 cells (Figure 4a ). Cytotoxicity assays with NCI-H929 cells were performed without any additional T-cell stimulation. As shown in Figure 4b , the bscWue-1 Â CD3 Ab was effective even at E:T ratios of 5:1.
Since the Wue-1 antigen has not been cloned so far, we further aimed at proving that the bscWue-1 Â CD3 Ab-mediated lysis of NCI-H929 cells is antigen specific. Therefore competition experiments with the monoclonal Wue-1 Ab were performed. As demonstrated in Figure 5 , incubation with an eight-fold molar excess of monoclonal Wue-1 Ab resulted in the strong inhibition of the cytotoxic activity of the bscWue-1 Â CD3 Ab. In contrast, the incubation with an appropiate isotype control antibody did not affect the cytotoxic activity.
bscWue-1 Â CD3 Ab induces specific lysis of primary human MM cells
After we demonstrated the specific cytotoxicity of the bscWue-1 Â CD3 Ab towards the MM cell line NCI-H929, we next tested whether this bsc antibody was also able to induce lysis of primary human MM cells. Tumor samples derived from 11 different MM patients were analyzed. The characteristics of these patients are summarized in Table 1 . The mean specific lysis of all patient samples (#1-11) analyzed with bscWue-1 Â CD3 in this study was 45.5% with a standard deviation (s.d.) of 723.8%. Based on this calculation, we defined 20% as cutoff level and scored lysis of primary MM cells below 20% as negative.
The cytotoxicity experiments were carried out in two different experimental settings. In the first setting, MM cells from bone marrow aspirates of MM patients were isolated and enriched by magnetic separation using the CD138 marker. The purified MM Table 2 , specific lysis of primary MM cells after the addition of 1 mg/ml bscWue-1 Â CD3 Ab could be observed in 6/8 cases analyzed, and ranged from 34 to 74%. Thereby, a specific lysis above 50% could be observed in most experiments. No significant difference was observed between medium control samples and samples with the bscEp-CAM Â CD3 control antibody (data not shown). From patient 3 enough MM cells were purified to perform a dose-response curve, suggesting that the maximal cytotoxic activity was not reached with 1 mg/ml of bscWue-1 Â CD3 in this specific experimental setting ( Figure 6 ). Cytotoxicity assays performed with CLL cells from two different patients as negative controls showed no or only minor lysis induced by the bscWue-1 Â CD3 Ab, but displayed high susceptibility to bscCD19 Â CD3-mediated cytotoxicity (Figure 7 ).
To approach the in vivo situation more closely a second experimental setting was established. Here, the unmanipulated mononuclear cell fraction containing both myeloma cells and effector T cells from the same bone marrow aspirate was used for cytotoxicity experiments. The E:T ratio in these samples reflects more likely the physiological conditions of the bone marrow because no further enrichment of myeloma cells or T cells was performed. The E:T ratio was determined by FACS analysis. The mononuclear cell fractions were incubated with the bscWue-1 Â CD3 Ab or the bscEpCAM Â CD3 control Ab without additional pre-or costimulation of the effector T cells.
Figure 5
Antigen specificity of cytotoxicity induced by bscWue-1 Â CD3 towards NCI-H929 cells. Cytotoxicity assay (48 h) with an eight-fold molar excess of monoclonal Wue-1 Ab or unspecific control Ig in the presence of bscWue-1 Â CD3 Ab (2 mg/ml) and an E:T-ratio of 10:1. Specific lysis was determined as described in Materials and methods. Experiments were performed with effector T cells isolated from three different random donors (T-cell samples #1-3). No stimulation of T cells was performed. Experiments were performed in triplicate, the s.d. is indicated. Primary human MM cells were isolated and enriched from bone marrow aspirates of eight different patients by immunomagnetic separation using the CD138 marker. PBMCs from healthy donors (allog.) or from the respective patients (autol.) were added resulting in an E:T ratio of 10:1. Cytotoxicity experiments were performed with bscWue-1 Â CD3 Ab at a concentration of 1 mg/ml. As unspecific T-cell stimuli PHA (10 ng/ml) and IL-2 (60 U/ml) were added at day 0. After 5-7 days, specific lysis was determined as described in Materials and methods. Depending on the amount of multiple myeloma cells obtained, one to three independent experiments were performed, and the specific lysis of each experiment is indicated in the last column. The bscEpCAM Â CD3 Ab was used as a negative control. Samples marked with * were scored as not having achieved specific cytotoxicity.
Figure 6
Dose-response curve of bscWue-1 Â CD3 with primary MM cells derived from patient 3. Cytotoxicity assay with primary MM cells from patient 3 (Table 1 ) with increasing amounts of bscWue-1 Â CD3 Ab at an E:T ratio of 10:1. As unspecific T-cell stimuli PHA (10 ng/ml) and IL-2 (60 U/ml) were added at day 0. Specific lysis was determined as described in Materials and methods. Experiments were performed with autologous T cells isolated from the peripheral blood of the same patient. Experiments were performed in duplicate.
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As shown in Table 3 , incubation with 2.5 mg/ml bscWue-1 Â CD3 Ab for 4 or 6 days resulted in specific lysis of primary MM cells in the range of 36-88%.
The mean specific lysis achieved with allogeneic T cells (# 2, 5, 6, 8) was 54.5% with an s.d. of 7 5.2%. The mean specific lysis achieved with autologous T cells (# 1, 3, 4, 7, 9, 10, 11) was 40.5% with an s.d. of 710.7%. This difference is not statistically significant as determined by the unpaired t-test (P ¼ 0.37). Thus, no significant difference in specific cytotoxicity between experiments with either autologous or allogeneic effector T cells could be observed.
Discussion
We have generated a novel recombinant MM cell-directed bsc antibody, designated bscWue-1 Â CD3. The antibody consists of two different single-chain Fv fragments joined by a glycineserine linker. One specificity is directed against the CD3 antigen of human T cells and the other antigen-binding site engages the recently described plasma cell-specific Wue-1 antigen. 12 The bscWue-1 Â CD3 Ab was cloned, expressed, and purified as previously described for similar bsc constructs. 34, 37 Specific binding of bscWue-1 Â CD3 to Wue-1-expressing cells was demonstrated by immunocytochemistry. We analyzed the biological activity of the recombinant bscWue-1 Â CD3 antibody using the human MM cell line NCI-H929 and primary myeloma cells freshly isolated from diagnostic bone marrow aspirates of 11 MM patients. We could demonstrate that bscWue-1 Â CD3 induces T-cell-mediated cytotoxicity against both the MM cell line and primary MM cells in nine out of 11 cases. No significant differences were found between samples containing autologous or allogeneic T cells. Since an allogeneic response is MHC restricted, this observation underscores the ability of bscWue-1 Â CD3 to elicit MHC-independent cytotoxicity. This could be of great importance for a potential clinical application of this antibody.
The bscWue-1 Â CD3 Ab-induced cytotoxic effects were target cell and antigen specific and were mediated by T cells as demonstrated by the following results:
(1) control bsc antibodies of different target specificity but identical molecular structure, bscEpCAM Â CD3 and bscCD19 Â CD3, failed to lyse myeloma cells, (2) cytotoxicity could be blocked by the Wue-1 monoclonal antibody, (3) the bscWue-1 Â CD3 Ab failed to lyse the B-lymphoma cell line NALM-6 that does not express the Wue-1 antigen, and (4) in the absence of T cells no cytotoxic effects of the bscWue-1 Â CD3 Ab could be observed.
In addition, we have shown the capability of the bscWue-1 Â CD3 Ab to induce MM cell-directed cytotoxicity with autologous T cells derived from the bone marrow of patients at an E:T ratio of 1:2 and without any additional T-cell pre-or costimulation. The fact that the bscWue-1 Â CD3 Ab is able to mediate specific cytotoxicity under these conditions is a promising property of the antibody with regard to its potential clinical application. This finding is also of interest in the context of previous reports about the presence of myelomaidiotype-specific T cells located in the bone marrow that seem to be dormant in MM patients with active disease. 45, 46 One could speculate that the bscWue-1 Â CD3 Ab might have the potential to activate these dormant myeloma-specific T cells, and thus might trigger a sustained myeloma-directed immune response.
The observation that bscWue-1 Â CD3 Ab-induced cytotoxicity is mediated by T cells at low E:T ratios without any need of additional pre-or costimulation is in accordance with previous studies using similar bsc antibodies of the same molecular format, for instance, bscEpCAM Â CD3 Ab and bscCD19 Â CD3 Ab. 35, 36 The findings with these single-chain antibodies are in sharp contrast to findings with conventional bispecific antibodies including bispecific antibody constructs that require much higher E:T ratios and extensive prestimulation (eg IL-2) or costimulation (for example, anti-CD28) of the effector T cells to be efficacious. [47] [48] [49] [50] [51] [52] [53] Thus, it seems that the biological characteristics described above are unique properties of this particular bsc format that discriminates these molecules from other T-cell recruiting bispecific antibodies generated until now. The mechanism underlying these biological properties is still unclear and under current investigation.
Previously, it has been reported that ligation of Wue-1 by the monoclonal antibody was able to enhance the proliferation of NCI-H929 cells. 12 Thus, one might speculate that a potential therapeutic effect of Wue-1 antibody constructs could be antagonized by the induction of myeloma cell proliferation. However, in our cytotoxicity experiments with the bscWue-1 Â CD3 antibody, a decrease (rather than increase) of the viable Lack of activity of bscWue-1 Â CD3 on CLL cells in contrast to bscCD19 Â CD3. Cytotoxicity assay with CLL cells from two different donors in the presence of bscWue-1 Â CD3 Ab (1 mg/ml) or bscCD19 Â CD3 (100 pg/ml). As unspecific T-cell stimuli PHA (10 ng/ml) and IL-2 (60 U/ml) were added at day 0. Specific lysis was determined as described in Materials and methods. Experiments were performed with effector T cells isolated from two different random donors. Experiments were performed in triplicate, the s.d. is indicated. bscWue-1 Â CD3 Ab (2.5 mg/ml) was added to the mononuclear cell fractions derived from bone marrow aspirates from three different MM patients. The proportion of T cells (CD3 + ) and MM cells (CD138 + ) in the respective aspirates was determined by FACS analysis at day 0. The resulting calculated E:T ratios (CD3 + :CD138 + ) are indicated. No additional effector T cells from the peripheral blood were added and no additional T-cell stimulation was performed. After 4 or 6 days, specific lysis was determined as described in Materials and methods.
bscWue-1 Â CD3 in the treatment of MM D Hönemann et al myeloma cell fraction was observed. Furthermore, in the presence of the bscWue-1 Â CD3 Ab alone no enhanced proliferation of NCI-H929 cells could be observed (data not shown). Therefore, we assume that an undesirable proliferative stimulus due to treatment with bscWue-1 Â CD3 is unlikely. Several investigators have reported on antibody-based immunotherapeutic approaches in MM using anti-CD38, anti-HM1.24, or anti-CD138 antibody constructs. However, since the targeted antigens are also expressed on various normal tissues including normal hematopoietic cells, these approaches might induce side effects. [13] [14] [15] [16] 54 In contrast, the expression of the Wue-1 antigen is restricted to normal and malignant plasma cells and could not be detected on other normal tissues or other normal cell types. 12 Among the anti-MM antibodies described previously, chimeric and humanized forms of anti-CD38 and anti-HM1.24 mAbs have been reported to show cytotoxic effects against myeloma cells in the presence of effector cells. The recently described humanized anti-HM1.24 mAb has been shown to mediate antibody-dependent cellular cytotoxicity against both myeloma cell lines and myeloma cells from patients in the presence of human peripheral blood mononuclear cells (PBMCs). To achieve efficient specific target cell lysis (30-40%), an E:T ratio of 50:1 to 100:1 was required in these experiments. 55 Similar results were obtained with a humanized anti-CD38 antibody, which was tested with the Wien-133 cell line and allogeneic T cells. 56 The cytotoxic potential of the anti-CD138 antibody B-B4 was tested primarily without effector cells as an immunotoxin conjugate in preclinical studies. 15, 57 In addition, sperm protein 17 (Sp17) was described as a suitable target for the immunotherapy of MM with antigen-specific cytotoxic T cells, but was not yet evaluated for an antibodybased immunotherapeutic approach. 58 In contrast, in our experiments with the bscWue-1 Â CD3 Ab using primary myeloma cells and autologous T cells, an E:T ratio of 1:2 was sufficient for myeloma cell lysis. Another possible advantage of the single-chain antibody construct presented compared to other plasma-cell-associated antibodies described, so far, may be its low molecular weight that might improve its penetration into malignant tissue, as has been shown for Fab or Fv antibody fragments. 39 With regard to immunogenicity of the covalently linked 4 V-regions devoid of all constant immunoglobulin domains, we anticipate a reduction in the HAMA (human anti-mouse antibody) response that has been observed with other conventional constructs.
In summary, we have shown that a recombinant bsc antibody, bscWue-1 Â CD3, specifically induces cytotoxicity against a human MM cell line and primary MM cells derived from bone marrow aspirates of patients. BscWue-1 Â CD3 is efficacious at low E:T ratios and without additional T-cell stimulation and, therefore, shares the exceptional biological properties with other members of this particular bsc format. To our knowledge, the bscWue-1 Â CD3 Ab is the first MM-directed bispecific antibody described so far, and the first immunotherapeutic approach directed towards the Wue-1 antigen, which has thus turned out to be a promising target for an antibody-based treatment of MM.
